Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?

Anna La Salvia, Emmanuele De Luca, Antonio Rossi, Massimo Di Maio

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish
Pages (from-to)1899-1902
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Issue number18
Publication statusPublished - Dec 12 2017


  • chemotherapy
  • epidermal growth factor receptor
  • Erlotinib
  • gefitinib
  • intercalated
  • resistance
  • T790M

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this